NOVARTIS AG NAMENS-AKTIEN SF 0,5
NOVARTIS AG NAMENS-AKTIEN SF 0,5/ CH0012005267 /
904278
|
07/09/2024 13:04:24
|
Chg.
-0.100
|
Volume |
Bid13:04:24 |
Demandez à13:04:24 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
|
104.440EUR
|
-0.10%
|
-
Chiffrre d'affaires: - |
104.440Bid taille: - |
105.860Ask la taille: - |
240.16 Mrd.EUR |
- |
- |
Description de l'entreprise
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis products are sold in approximately 155 countries around the world.
Conseil d'administration & Conseil de surveillance
| PDG |
| Vasant Narasimhan, M.D. |
| Conseil d'administration |
| Harry Kirsch, Dr. Klaus Moosmayer, Dr. Steffen Lang, Karen L. Hale, Rob Kowalski, Shreeram Aradhye, Victor Bulto, Aharon (Ronny) Gal, Dr. Fiona H. Marshall, Patrick Horber |
| Conseil de surveillance |
| Dr. Joerg Reinhardt, Bridgette Heller, Charles L. Sawyers, M.D., Dr. Charlotte Pamer-Wieser, Dr. Nancy C. Andrews, Elizabeth Doherty, Frans van Houten, Simon Moroney, Ton Buechner, William T. Winters, Daniel Hochstrasser, Ana de Pro Gonzalo, John D. Young, Patrice Bula |
Données de l'entreprise
| Nom: |
Novartis AG |
| Adresse: |
Lichtstrasse 35,CH-4002 Basel |
| Téléphone: |
+41-61-324-1111 |
| Fax: |
+41-61-324-8001 |
| Courriel: |
-
|
| Internet: |
www.novartis.com |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
86.85% |
| IPO date: |
07/03/1996 |
Calendrier de l'entreprise
|
CW 44 | 29/10/2024
Interim Report 3rd Quarter/9 Months
|
